Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 2010. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on specific share transactions rather than general financial performance.
Material Changes
The filing reports an increase in share interests for two individuals following the re-investment of dividends paid on July 8, 2010. The shares were purchased on July 14, 2010, at a price of £11.78 per share.
- Dr M M Slaoui: Acquired 314 Ordinary shares.
- Mr M Dunoyer: Acquired 151 Ordinary shares.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the routine notification of director share purchases.
Investor Verification Points
- Verify the total number of shares held by Dr M M Slaoui and Mr M Dunoyer post-transaction.
- Confirm the dividend reinvestment mechanism details for the GlaxoSmithKline Annual Investment Plan.
- Check the market price of GSK shares on July 14, 2010, to validate the £11.78 transaction price.